How to assess medical polymer biocompatibility under ISO 10993

A polymer catheter can meet flexibility and burst-pressure targets yet still raise biological concerns after coating, bonding, and sterilization. A PEEK implant may have extensive material-history data while its finished surface carries machining residues that those data never addressed. These gaps can trigger additional testing, redesign, or questions during regulatory review.

Assess medical polymer biocompatibility by evaluating the finished device within an ISO 10993 risk-management process: define patient contact and exposure, characterize materials and manufacturing-related hazards, assess existing evidence, and close specific biological safety gaps. ISO 10993 is not a universal test checklist, and a resin supplier’s “biocompatible” designation does not establish the safety of your device.

Start with the device configuration, not the resin certificate

The first practical task is to define exactly what is being evaluated. For medical polymer technology materials, biological behavior depends on formulation, processing, surface condition, and clinical exposure—not simply whether the base polymer is silicone, polyurethane, polyethylene, or PEEK.

Prepare a biological evaluation plan before commissioning laboratory work. Link it to the device risk-management file and identify the applicable edition of ISO 10993-1, together with relevant supporting standards. Confirm which editions and regulatory guidance your target jurisdiction accepts; publication of a revised standard does not automatically mean every authority has adopted it.

The plan should establish:

• Device boundaries: patient-contacting components, coatings, adhesives, accessories, and fluid-path materials that can transfer substances to the patient.
• Clinical use: anatomical location, intended users and patients, contact conditions, and foreseeable exposure during use.
• Manufacturing state: formulation, suppliers, cleaning, joining, printing or machining, packaging, and sterilization.
• Evidence strategy: existing information, unresolved hazards, proposed characterization or testing, and criteria for accepting the residual biological risk.

Keep this plan separate from the final biological evaluation report. The plan explains how evidence will be generated and assessed; the report documents what the evidence actually supports.

Translate clinical use into contact and exposure

A catheter’s external hub, intravascular shaft, and infusion pathway may create different exposure routes. Classifying the entire assembly under a single convenient label can overlook indirect patient contact or overstate exposure for components that never contact the patient.

Use the contact categories and duration definitions in the applicable ISO 10993-1 edition. Record whether contact involves intact skin, compromised surfaces, tissue, circulating blood, or another relevant site. Consider cumulative exposure where a device is used repeatedly, rather than classifying each brief use in isolation.

For repeated procedures, document use frequency, replacement intervals, and the basis for the exposure calculation. Where clinical use is uncertain, resolve that uncertainty through the intended-use specification or a justified conservative assumption.

Build a material and process hazard map

A supplier certificate is useful supporting evidence, but it rarely describes every substance relevant to a finished device. Request composition information at a level sufficient for biological risk assessment, including additives and known residuals. Confidential formulation details may require controlled disclosure to the evaluating toxicologist or laboratory.

Map potential hazards to their sources. Polyurethane chemistry may introduce residual reactants or degradation concerns; plasticized tubing may release additives; bonded assemblies may retain adhesive constituents. Mold-release agents, detergents, inks, machining fluids, and packaging-derived substances can also matter even though they are not part of the nominal polymer formulation.

Separate chemical hazards from physical and surface-related hazards. Extractables analysis cannot, by itself, establish the safety of coating fragments, wear debris, rough surfaces, or geometry-dependent tissue injury. Likewise, a chemically well-characterized catheter may still require evaluation of relevant blood interactions.

Existing data can reduce new work when applicability is demonstrated. Compare formulation, manufacturing, sterilization, contact, exposure, and device geometry. “Same polymer family” is not enough to bridge a new device to an older biological test report.

Use chemical characterization to investigate exposure

ISO 10993-18 provides a framework for chemical characterization. Depending on available knowledge and identified gaps, this can include composition review, extractables testing, and studies that better represent substances released during clinical use. Define the analytical question before selecting extraction conditions.

Extractables and leachables answer different questions. Exaggerated or exhaustive extraction helps identify substances that could be released under specified laboratory conditions. Simulated-use or other clinically relevant leachables work helps estimate actual patient exposure. Neither approach should be interpreted without considering its relationship to use.

Extraction design should account for solvent polarity, temperature, time, device surface area or mass, and the sensitivity needed for the assessment. ISO 10993-12 supports sample preparation and extraction decisions. Conditions that dissolve a polymer or create unrealistic degradation products need careful interpretation rather than automatic treatment as clinically representative.

Ask the analytical laboratory to document:

• The rationale for extraction conditions and sample preparation.
• Coverage of relevant volatile, semi-volatile, non-volatile, and elemental constituents, as appropriate.
• The analytical evaluation threshold and the exposure assumptions behind it.
• Identification confidence, quantification uncertainty, blanks, and analytical limitations.
• How unidentified or incompletely identified substances will be addressed.

An analytical evaluation threshold is a reporting and identification tool, not a universal safety limit. A substance reported below a threshold is not automatically harmless, particularly where specific high-concern constituents warrant targeted analysis.

Convert chemical findings into a toxicological assessment

A chromatogram is not a biological safety conclusion. Under ISO 10993-17, relevant chemical findings are assessed using patient exposure estimates, toxicological information, applicable tolerable exposure values, and uncertainty. The analysis should explain why the available evidence is adequate for the route and duration of exposure.

Check the calculation inputs closely. Device count per procedure, extract volume, recovery assumptions, patient body mass, exposure frequency, and release kinetics can materially change the conclusion. Treating all extracted material as a single-day exposure may be conservative in one situation but inappropriate for another; averaging exposure across an implant’s lifetime can obscure an early release peak.

Where toxicological information is limited, a justified threshold-based approach may be possible within its applicability limits. It should not be used indiscriminately for excluded chemical classes, unidentified substances, or biological effects that the chosen approach does not address.

Unresolved findings may require better substance identification, targeted leachables testing, revised exposure estimates, additional biological evidence, or a material/process change. Repeating the same broad screen without addressing the uncertainty rarely improves the assessment.

Select biological endpoints from the remaining gaps

The applicable ISO 10993-1 framework helps identify biological effects that require consideration. It does not mean every effect requires a new animal or laboratory test. For each relevant endpoint, document whether existing evidence is sufficient, further analysis is needed, or testing is justified.

Cytotoxicity under ISO 10993-5 can reveal harmful effects associated with materials or residues, but a passing result does not establish sensitization, systemic, implantation, or blood compatibility. Sensitization and irritation are addressed through distinct approaches, including ISO 10993-10 and ISO 10993-23 respectively, where applicable.

Blood-contacting devices require particular attention to ISO 10993-4. Depending on the device and contact conditions, evaluation may involve hemolysis, thrombosis, coagulation, platelets, or complement. A static extract assay cannot substitute for every interaction that occurs at a blood-contacting surface under flow.

Implantation assessment under ISO 10993-6 addresses local tissue responses. Systemic toxicity, genotoxicity, and other effects need consideration when indicated by contact, chemistry, exposure, and available evidence. Avoid assuming that long-term contact automatically dictates the same test package for every polymer device.

For absorbable polymers, evaluate the degradation profile and products, not only the original material. Changes in molecular weight, local conditions, particle formation, and exposure over time can alter risk. Relevant parts of the ISO 10993 series address degradation and polymer degradation products.

Make test samples represent the marketed device

Testing an unsterilized resin plaque may be convenient, but it can miss the effects of extrusion, bonding, coating, cleaning, and sterilization. Use the final finished device whenever appropriate, including relevant packaging and sterilization effects. Any alternative test article needs a documented representativeness argument.

For a device family, select worst-case configurations against defined hazards. The greatest surface area may drive chemical exposure, while the highest adhesive loading or most severe processing condition may drive another concern. One model is not automatically worst case for every endpoint.

Sterilization requires explicit treatment. Ethylene oxide processing introduces residual concerns addressed by ISO 10993-7 where applicable. Radiation can change polymer chemistry; other sterilization processes can also affect additives and surfaces. Consider maximum permitted processing exposure, repeated sterilization where relevant, and aging when these could change biological safety.

A cytotoxicity failure should trigger a structured investigation: verify controls and extraction conditions, examine manufacturing and cleaning records, and assess laboratory or sampling issues. Do not dismiss a failed result as an assay artifact without evidence, or repeatedly retest until an acceptable result appears.

Close the evaluation with traceable decisions

The biological evaluation report should connect each identified hazard to evidence and a reasoned conclusion. Include device identification, contact classification, material and process information, study applicability, chemical and toxicological assessments, test results, uncertainties, and any remaining risk controls. Record the qualifications and responsibilities of those performing the evaluation.

ISO 10993 conformity is not a standalone product approval or universal material certificate. The biological evaluation supports the device’s broader safety and regulatory submission. Its adequacy depends on the intended use, evidence quality, and jurisdiction-specific expectations.

Maintain the evaluation after design release. A new resin supplier, pigment, adhesive, coating cure, cleaning agent, sterilization cycle, or manufacturing site should enter change control with a biological impact assessment. Where the change can alter exposure or introduce hazards, update the affected evidence before assuming that previous conclusions still apply.